Developing new materials to improve cancer treatment for multiple myeloma
Engineering Biomaterials to Modulate the Tumor Immune Microenvironment
['FUNDING_OTHER'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11232006
This study is exploring new ways to treat multiple myeloma by using special materials to deliver targeted therapies that can help make current treatments work better, giving patients more options to fight their cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11232006 on ClinicalTrials.gov |
What this research studies
This research focuses on finding innovative therapies for multiple myeloma, a type of blood cancer that is often resistant to current treatments. The approach involves engineering biomaterials that can effectively deliver RNA interference therapies to target specific proteins that help cancer cells survive and spread. By inhibiting these proteins, the goal is to enhance the effectiveness of existing treatments and overcome drug resistance. Patients may benefit from new therapeutic options that are designed to be more effective against their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who have not responded well to current therapies.
Not a fit: Patients with other types of cancers or those who have not been diagnosed with multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for multiple myeloma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using RNA interference therapies for cancer treatment, indicating that this approach could be a viable option.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FIGUEROA-ESPADA, CHRISTIAN GABRIEL — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: FIGUEROA-ESPADA, CHRISTIAN GABRIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy